LIFEVANTAGE CORP Form PREC14A: Preliminary proxy statement in a contested solicitation
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-09-15: Form PREC14A; Description Preliminary proxy statement in a contested solicitation; Document prec14a09076057_09152023.htm.
- 2023-09-08: Form PREC14A; Description PREC14A; Document lfvnpreliminaryproxystatem.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2023-09-15 | PREC14A | Preliminary proxy statement in a contested solicitation | prec14a09076057_09152023.htm | |
| 2023-09-08 | PREC14A | PREC14A | lfvnpreliminaryproxystatem.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |